RAR-Related Orphan Receptor Gamma Modulators, Pipeline Insights, 2016; New Report Launched

RAR-Related Orphan Receptor Gamma (RORγ) Modulators Pipeline Insights, 2016 report provides comprehensive insights about pipeline drugs across this mechanism of action. The Report gives insights on 20+ products, 18+ companies that are active in this field and 10+ indications that are being targeted by RAR-Related Orphan Receptor Gamma (RORγ) Modulators.

This report provides information on the therapeutic development based on the RAR-Related Orphan Receptor Gamma (RORγ) Modulators dealing with all the pipeline drugs, comparative analysis of RAR-Related Orphan Receptor Gamma (RORγ) Modulators at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information.

The report also covers the company’s information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products. This Report will help you to identify emerging players with potentially strong product information, licensing opportunities and helps you to create effective counter-strategies to gain competitive advantage.

Report Highlights:

• The new report, provides a RAR-Related Orphan Receptor Gamma (RORγ) Modulators Landscape across the globe
• The report provides drug profiles which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Preclinical and Discovery stages
• Coverage of the RAR-Related Orphan Receptor Gamma (RORγ) Modulators based pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• Pipeline products coverage based on various stages of development from NDA filings to discovery.
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.

Spanning over 80 pages, 11 Tables and 10 Figures “RAR-Related Orphan Receptor Gamma (RORγ) Modulators, Pipeline Insights, 2016” report covers RAR-Related Orphan Receptor Gamma (RORγ) Modulators Overview, Pipeline Therapeutics, Comparative Analysis, Therapeutic Assessment, Appendix. This report Covered 9 Companies - Glaxo Smith Kline, Bristol Meyer Squibb, Amgen, Japan Tobacco Company, Krish Biotech, Lead Pharma, Karo Biotech, Vitae Pharmaceuticals, Arrien Pharmaceuticals.

For more information Visit at: http://mrr.cm/JRr

Find all Drug Discovery Reports at: http://www.marketresearchreports.com/drug-discovery